Replies to post #179688 on Biotech Values

[IanFromSI]

Another deal by CGIX. Last week they did the collaboration deal with MRK.

Any thoughts re their management? Astute or desperate re their competitive prospects against FMI?

Thanks,
Ian


RE:

8:39 am Cancer Genetics to acquire Gentris Corp for ~$4.75 mln (CGIX) : Cancer Genetics announces the signing of a non-binding Letter of Intent to acquire privately held Gentris Corporation, a co focused on pharmacogenomics solutions, biomarker testing and biorepository services for ~$4.75 mln, comprised of $3.25 million in cash, $1.5 million in CGI stock as well as additional performance-based earnouts of up to $1.5 million.

The transaction, which will be treated as an asset purchase, is expected to close during the third quarter of 2014.
Gentris advances personalized medicine by partnering with pharmaceutical, academic and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly and improving patient care.
It has extensive experience with GLP and CLIA regulations and with regulatory agencies and guidance in the United States, Europe, China and Japan.

[DewDiligence]

Speculation about tax inversions involving SYT:

http://www.bloomberg.com/news/2014-08-27/no-monsanto-no-problem-for-syngenta-real-m-a.html

The prospective buyer could be DD or DOW, but not MON.